Genome & Company (314130)

Overview

Genome & Company is a pioneering entity in the biotech industry, primarily operating in the clinical stage with a focus on developing innovative immuno-oncology therapeutics. Founded in 2015 and headquartered in Seongnam-si, South Korea, the company is at the forefront of research in immuno-oncology, skin diseases, and autism. Leveraging state-of-the-art biotechnological innovations, Genome & Company is dedicated to producing novel targeted treatments intended to significantly improve patient outcomes in areas of high unmet medical need. Its strategic partnerships, notably with US-based Scioto Biosciences, underscore its commitment to expanding the therapeutic potential of its research beyond national borders, targeting global health challenges.

Products and Services

• GEN-001

As the lead product candidate of Genome & Company, GEN-001 is an oral microbiome therapeutic designed to harness immune modulating activities. This innovation represents the company's endeavors in immuno-oncology, aiming to provide a novel treatment approach by modulating the body's natural immune responses.

• GEN-501

Targeting the non-responders of Dupilumab drugs, GEN-501 is currently under development for patients with atopic skin diseases. This product underscores Genome & Company’s commitment to addressing the limitations of current therapies and enhancing treatment options for patients with skin conditions.

• GENA-104

With a focus on oncology, GENA-104 is being developed for the treatment of solid tumors. This therapeutic candidate represents the company’s efforts in extending the horizons of immuno-oncology treatment, aiming to offer new hope to patients battling solid tumors.

• Microbiome-based Products

Genome & Company’s portfolio also includes an array of microbiome-based products, ranging from therapeutics to cosmeceuticals and dietary supplements. These products highlight the company's broader interest in leveraging the human microbiome for health and wellness solutions beyond traditional therapeutics.

• SB-121 Partnership with Scioto Biosciences

Through its partnership with Scioto Biosciences, Genome & Company is involved in the development of SB-121, a promising candidate targeting disorders related to the gut-brain axis, including Autism Spectrum Disorder (ASD) and gut-injury related disorders such as Necrotizing Enterocolitis (NEC). This collaboration reflects the company’s innovative approach to addressing complex health issues by targeting foundational causes of the disorders.